Literature DB >> 30103321

Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study.

Fermín Segovia1,2, Manuel Gómez-Río3,4, Raquel Sánchez-Vañó5,6, Juan Manuel Górriz1,2,4, Javier Ramírez1,2,4, Eva Triviño-Ibáñez3,4, Cristóbal Carnero-Pardo4,7, María Dolores Martínez-Lozano8, Pablo Sopena-Novales5.   

Abstract

BACKGROUND: Biomarkers of neurodegeneration play a major role in the diagnosis of Alzheimer's disease (AD). Information on both amyloid-β accumulation, e.g., from amyloid positron emission tomography (PET), and downstream neuronal injury, e.g., from 18F-fluorodeoxyglucose (FDG) PET, would ideally be obtained in a single procedure.
OBJECTIVE: On the basis that the parallelism between brain perfusion and glucose metabolism is well documented, the objective of this work is to evaluate whether brain perfusion estimated in a dual-point protocol of 18F-florbetaben (FBB) PET can be a surrogate of FDG PET in appropriate use criteria (AUC) for amyloid PET.
METHODS: This study included 47 patients fulfilling international AUC for amyloid PET. FDG PET, early FBB (pFBB) PET (0-10 min post injection), and standard FBB (sFBB) PET (90-110 min post injection) scans were acquired. Results of clinical subjective reports and of quantitative region of interest (ROI)-based analyses were compared between procedures using statistical techniques such as Pearson's correlation coefficients and t-tests.
RESULTS: pFBB and FDG visual reports on the 47 patients showed good agreement (k  >  0.74); ROI quantitative analysis indicated that both data modalities are highly correlated; and the t-test analysis does not reject the null hypothesis that data from pFBB and FDG examinations comes from independent random samples from normal distributions with equal means and variances.
CONCLUSIONS: A good agreement was found between pFBB and FDG data as obtained by subjective visual and quantitative analyses. Dual-point FBB PET scans could offer complementary information (similar to that from FDG PET and FBB PET) in a single procedure, considering pFBB as a surrogate of FDG.

Entities:  

Keywords:  Alzheimer’s disease; FDG PET; amyloid PET; appropriate use criteria; brain perfusion; brain rCBF; brain rCMRglc; florbetaben PET; mild cognitive impairment; quantitative analysis

Mesh:

Substances:

Year:  2018        PMID: 30103321     DOI: 10.3233/JAD-180232

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  3 in total

1.  Correlation of Early-Phase F-18 Florapronal PET with F-18 FDG PET in Alzheimer's Disease and Normal Brain.

Authors:  Jieun Jeong; Young Jin Jeong; Kyung Won Park; Do-Young Kang
Journal:  Nucl Med Mol Imaging       Date:  2019-09-11

2.  Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria.

Authors:  Eva María Triviño-Ibáñez; Raquel Sánchez-Vañó; Pablo Sopena-Novales; Juan Carlos Romero-Fábrega; Antonio Rodríguez-Fernández; Cristóbal Carnero Pardo; María Dolores Martínez Lozano; Manuel Gómez-Río
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

3.  Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated.

Authors:  Young-Sil An; Jung Han Yoon; Sang Joon Son; Chang Hyung Hong; Su Jin Lee; Joon-Kee Yoon
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.